



# National Coalition of STD Directors

	Final FY17 Funding (Omnibus)	Final FY18 Funding (Omnibus)	Amount Change from FY17 Omnibus	Percentage Increase /Decrease from FY17	President's FY19 Budget Proposal
Centers for Disease Control and Prevention	\$7.3 b	\$8.3 b	+\$1 b	+13.7%	
CDC - National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Infections (STIs), and Tuberculosis Prevention	\$1.117 b	\$1.127 b	+\$10 m	+0.9%	\$1.117 b
CDC - Division of STD Prevention (DSTDP)	\$152.3 m	\$157.3 m	+\$5 m	+3.3%	\$152.3 m
CDC - Division of HIV/AIDS Prevention (DHAP) <sup>1</sup>	\$755.6 m	\$755.6 m	(\$0)	(0%)	\$748.7 m
CDC- Division of Adolescent and Sexual Health (DASH)	\$33.1 m	\$33.1 m	(\$0)	(0%)	TBD <sup>2</sup>
CDC – Division of Viral Hepatitis	\$34 m	\$39 m	+\$5 m	+14.7%	\$34 m
CDC – Division of Tuberculosis Elimination	\$142.3 m	\$142.3 m	(\$0)	(0%)	\$142.2 m
HRSA- Ryan White Part A	\$655.9 m	\$655.9 m	(\$0)	(0%)	\$655.9 m
HRSA- Ryan White Part B	\$1.315 b	\$1.315 b	(\$0)	(0%)	\$1.315 b
HRSA- Ryan White Part C	\$201.1 m	\$201.1 m	(\$0)	(0%)	\$201.1 m
HRSA- Ryan White Part D	\$75.1 m	\$75.1 m	(\$0)	(0%)	\$75.1 m
HRSA- Ryan White Part F (SPNS)	\$25.0 m	\$25.0 m	(\$0)	(0%)	\$0
HRSA-Ryan White Part F (AETCs)	\$33.6 m	\$33.6 m	(\$0)	(0%)	\$0
HRSA- Community Health Centers	\$5.1 b	\$5.235 b	+\$135 m	+2.6%	\$5.1 b
HRSA- Title V Maternal and Child Health Block Grant	\$641.7 m	\$651.7 m	+\$10 m	+1.6%	\$628 m
HRSA- Title X Family Planning Program	\$286.5 m	\$286.5 m	(\$0)	(0%)	\$286.5 m

<sup>1</sup> Funding level is different from the level for “HIV Prevention” in the FY17 and FY18 bills, because this is funding only for DHAP and does not include funding for DASH.

<sup>2</sup> DASH is funded as part of the “HIV Prevention” line in both the President’s Budget and the Congressional funding bills. Additional detail is need regarding the President’s Budget to determine what the funding amount is for DASH.

<sup>3</sup> NIH received a \$3 b increase in FY18 funding. The office of AIDS Research and STD research is done across multiple Institutes; this will be updated when additional information is available.

<sup>4</sup>The National Institute of Allergy and Infectious Disease conducts clinical research on STDs. STD funding across institutes is reflected in the “NIH- Sexually Transmitted Diseases/Herpes Research” line

<sup>5</sup>Across multiple Institutes.



## National Coalition of STD Directors

Teen Pregnancy Prevention Program (TPPP)	\$101.0 m	\$101.0 m	(\$0)	(0%)	\$0
Secretary's Minority AIDS Initiative (MIA)	\$53.9 m	\$53.9	(\$0)	(0%)	TBD
Housing for People Living with AIDS (HOPWA)	\$356 m	\$375 m	+\$19 m	+5.3%	\$330.0 m
NIH- Office of AIDS Research	\$2.99 b	TBD <sup>3</sup>			TBD <sup>3</sup>
NIH- National Institute of Allergy and Infectious Disease <sup>4</sup>	\$4.9	\$5.3 b	+400 m	+8.1%	\$4.8 m
NIH- Sexually Transmitted Diseases/Herpes Research <sup>5</sup>	\$264 m	TBD <sup>3</sup>			TBD <sup>3</sup>

<sup>1</sup> Funding level is different from the level for "HIV Prevention" in the FY17 and FY18 bills, because this is funding only for DHAP and does not include funding for DASH.

<sup>2</sup> DASH is funded as part of the "HIV Prevention" line in both the President's Budget and the Congressional funding bills. Additional detail is need regarding the President's Budget to determine what the funding amount is for DASH.

<sup>3</sup> NIH received a \$3 b increase in FY18 funding. The office of AIDS Research and STD research is done across multiple Institutes; this will be updated when additional information is available.

<sup>4</sup>The National Institute of Allergy and Infectious Disease conducts clinical research on STDs. STD funding across institutes is reflected in the "NIH- Sexually Transmitted Diseases/Herpes Research" line

<sup>5</sup>Across multiple Institutes.